Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, Olema reports key information about its operations, financing activities, and clinical programs through forms such as 8-K, as well as registration statements and prospectus supplements.
Recent Olema 8-K filings include disclosures about an underwritten public offering of common stock conducted under an effective shelf registration statement on Form S-3, the termination of an at-the-market (ATM) prospectus under a sales agreement with TD Securities (USA) LLC, and clinical collaboration agreements with Pfizer to evaluate palazestrant plus atirmociclib in ER+/HER2- metastatic breast cancer. Other 8-Ks furnish press releases reporting quarterly financial results and updated data from Phase 1b/2 studies of palazestrant in combination with ribociclib in advanced or metastatic ER+/HER2- breast cancer.
Through Olema’s SEC filings, investors can review details of its capital-raising transactions, such as the size and terms of public offerings, the use of shelf registration statements on Form S-3, and the structure of underwriting agreements. Filings also identify the company’s registered securities, including its common stock listed under the symbol OLMA on The Nasdaq Global Select Market.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand material events, financial updates, and clinical or collaboration disclosures. Users can monitor new 8-Ks and other SEC reports in real time, track changes related to Olema’s clinical-stage oncology programs, and reference historical filings to follow the evolution of its palazestrant and OP-3136 pipelines and financing history.
Bain Capital Life Sciences Opportunities IV, L.P. has reported a passive ownership stake in Olema Pharmaceuticals, Inc. common stock on a Schedule 13G/A. As of December 31, 2025, it is deemed to beneficially own 8,508,641 shares, representing 9.99% of the outstanding common stock.
The position consists of 1,989,775 common shares and pre-funded warrants initially exercisable for up to 8,013,216 additional shares, but a 9.99% “Beneficial Ownership Blocker” caps how many warrant shares are counted for regulatory purposes. The filing states the securities were not acquired to change or influence control of Olema.
Olema Pharmaceuticals, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report that they now beneficially own 0 shares of Olema common stock, representing 0.00% of the class.
The filing confirms they have no sole or shared voting or dispositive power over Olema shares and that they own 5% or less of the outstanding common stock. Ownership percentages are calculated using 78,652,730 Olema common shares outstanding as of November 19, 2025, as disclosed in the company’s prospectus.
Olema Oncology insider plans additional stock sale under Rule 144. A holder has filed to sell 10,000 shares of Olema common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $238,498.19, targeting an approximate sale date of 02/12/2026.
The 10,000 shares were acquired on 06/15/2020 via restricted stock vesting from the issuer as compensation. In the past three months, the same seller disposed of 3,822 common shares for gross proceeds of $107,069.20 and 100,000 common shares for gross proceeds of $2,873,214.99.
FMR LLC, a Delaware entity, has filed a Schedule 13G reporting beneficial ownership of 5,023,092.35 shares of Olema Pharmaceuticals, Inc. common stock, representing 6.3% of the class as of 12/31/2025. These shares give FMR LLC sole voting power over 5,015,265 shares and sole dispositive power over 5,023,092.35 shares.
Abigail P. Johnson, a U.S. citizen, is also reported as a beneficial owner with sole dispositive power over the same 5,023,092.35 shares and a 6.3% stake, but no sole or shared voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema Pharmaceuticals.
Olema Pharmaceuticals, Inc. reported that Chief Medical Officer Naseem Zojwalla received two stock option awards on February 2, 2026. She was granted stock options for 250,000 shares of common stock at an exercise price of $25.65 per share, vesting 25% on February 2, 2027 and then in equal monthly installments over the following 36 months, contingent on continued service.
She also received performance stock options covering 106,250 shares at the same exercise price. These are eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds over a 30‑day average, and subject to her continued service when the Compensation Committee certifies achievement.
Olema Pharmaceuticals granted new equity awards to a senior executive. Chief Discovery & Non-Clinical Development Officer Myles David C. received stock options for 250,000 shares at an exercise price of $25.65 per share, expiring on February 1, 2036.
For this time-based option, 25% of the shares vest on February 2, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service. He also received 106,250 performance-based stock options at the same exercise price, eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds and continued service at the certification dates.
Olema Pharmaceuticals’ chief legal officer, Shawnte Mitchell, received new stock-based awards. On February 2, 2026, Mitchell was granted stock options to buy 220,000 shares of common stock at an exercise price of $25.65 per share, expiring February 1, 2036.
These time-based options vest 25% on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. Mitchell was also granted 56,250 performance-based stock options at the same $25.65 exercise price, also expiring February 1, 2036.
The performance options may vest in two performance periods beginning February 2, 2026 and ending December 31, 2029 and December 31, 2030, if Olema’s stock achieves specified average price thresholds over a 30-day trading period and the compensation committee certifies achievement, subject to Mitchell’s continued service.
Olema Pharmaceuticals reported new equity awards to President and CEO Sean Bohen. On February 2, 2026, he received a stock option to buy 850,000 shares at an exercise price of $25.65. These options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years, subject to continued service.
On the same date, Bohen also received 275,000 performance-based stock options at an exercise price of $25.65. These can vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, if Olema’s share price meets specified thresholds over a 30-day trading average and the compensation committee certifies achievement. If his service is terminated without cause, these performance options remain eligible to vest for 12 months.
Olema Pharmaceuticals announced that Chief Operating and Financial Officer Shane Kovacs is leaving the company effective January 30, 2026, to pursue new opportunities. He will remain as a consultant through August 1, 2026, and his existing equity awards will continue to vest during this period.
Under a separation and consulting agreement, Kovacs will receive a lump-sum payment of $621,283, including $562,640 (12 months of base salary), $23,443 (pro-rated 2026 target bonus at 100% achievement), and $35,200 for COBRA health coverage gross-up. The company states his departure is not due to any disagreement over financial operations, policies, or practices. CEO Sean Bohen, M.D., Ph.D., has taken on the role of interim principal financial officer until a new Chief Financial Officer is appointed.
Olema Pharmaceuticals director Cyrus Harmon reported a sale of company stock. On January 20, 2026, he sold 10,000 shares of Olema Pharmaceuticals common stock at a weighted average price of $26.88 per share, with individual trade prices ranging from $26.85 to $26.96. Following this transaction, he directly held 727,770 common shares.
The filing also notes an additional 117,028 common shares held indirectly through Harmon Family Investors LLC, where Harmon serves as manager, reflecting his indirect beneficial ownership interest alongside his direct holdings.